These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37418539)

  • 41. Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases.
    Aublette MC; Harrison TA; Thorpe EJ; Gadd MS
    Bioorg Med Chem Lett; 2022 May; 64():128636. PubMed ID: 35231578
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
    Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
    Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
    Ito T; Yamaguchi Y; Handa H
    Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection.
    Zahid S; Ali Y; Rashid S
    J Biomol Struct Dyn; 2023; 41(23):14566-14581. PubMed ID: 36841549
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes.
    Zaidman D; Prilusky J; London N
    J Chem Inf Model; 2020 Oct; 60(10):4894-4903. PubMed ID: 32976709
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tubulin Resists Degradation by Cereblon-Recruiting PROTACs.
    Gasic I; Groendyke BJ; Nowak RP; Yuan JC; Kalabathula J; Fischer ES; Gray NS; Mitchison TJ
    Cells; 2020 Apr; 9(5):. PubMed ID: 32349222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
    Singh H; Agrawal DK
    Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
    Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
    Eur J Med Chem; 2021 Nov; 223():113645. PubMed ID: 34217059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues.
    Yamanaka S; Horiuchi Y; Matsuoka S; Kido K; Nishino K; Maeno M; Shibata N; Kosako H; Sawasaki T
    Nat Commun; 2022 Jan; 13(1):183. PubMed ID: 35013300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. cIAP1-based degraders induce degradation via branched ubiquitin architectures.
    Akizuki Y; Morita M; Mori Y; Kaiho-Soma A; Dixit S; Endo A; Shimogawa M; Hayashi G; Naito M; Okamoto A; Tanaka K; Saeki Y; Ohtake F
    Nat Chem Biol; 2023 Mar; 19(3):311-322. PubMed ID: 36316570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The emerging role of targeted protein degradation to treat and study cancer.
    Brodermann MH; Henderson EK; Sellar RS
    J Pathol; 2024 Aug; 263(4-5):403-417. PubMed ID: 38886898
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advancing targeted protein degrader discovery by measuring cereblon engagement in cells.
    Zerfas BL; Huerta F; Liu H; Du G; Gray NS; Jones LH; Nowak RP
    Methods Enzymol; 2023; 681():169-188. PubMed ID: 36764756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CRBN ligand expansion for hematopoietic prostaglandin D
    Osawa H; Kurohara T; Ito T; Shibata N; Demizu Y
    Bioorg Med Chem; 2023 Apr; 84():117259. PubMed ID: 37018877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cereblon: promise and challenges for combating human diseases.
    Kim HK; Seol JE; Ahn SW; Jeon S; Park CS; Han J
    Pflugers Arch; 2021 Nov; 473(11):1695-1711. PubMed ID: 34553266
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide.
    Tateno S; Iida M; Fujii S; Suwa T; Katayama M; Tokuyama H; Yamamoto J; Ito T; Sakamoto S; Handa H; Yamaguchi Y
    Sci Rep; 2020 Mar; 10(1):4012. PubMed ID: 32132601
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of AMPK Activity by CRBN Is Independent of the Thalidomide-CRL4
    Yang SJ; Jeon S; Baek JW; Lee KM; Park CS
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
    Li D; Yu X; Kottur J; Gong W; Zhang Z; Storey AJ; Tsai YH; Uryu H; Shen Y; Byrum SD; Edmondson RD; Mackintosh SG; Cai L; Liu Z; Aggarwal AK; Tackett AJ; Liu J; Jin J; Wang GG
    Oncogene; 2022 Jun; 41(24):3328-3340. PubMed ID: 35525905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.